ARVN

Arvinas, Inc.

45.97 USD
-2.04 (-4.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arvinas, Inc. stock is up 16.47% since 30 days ago. The next earnings date is May 3, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 34% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
15 Feb 15:26 15 Mar, 2024 50.00 CALL 100 63
15 Feb 16:05 15 Mar, 2024 55.00 CALL 190 91
16 Feb 15:59 19 Jul, 2024 40.00 CALL 20 36
16 Feb 16:22 19 Apr, 2024 55.00 CALL 82 13
16 Feb 16:23 19 Apr, 2024 55.00 CALL 77 13
16 Feb 16:23 19 Apr, 2024 55.00 CALL 74 13
16 Feb 17:33 15 Mar, 2024 50.00 PUT 150 877
21 Feb 18:52 18 Oct, 2024 55.00 PUT 21 0
27 Feb 17:45 19 Jul, 2024 50.00 CALL 30 277
28 Feb 17:34 19 Apr, 2024 50.00 CALL 80 89

About Arvinas, Inc.

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

  • Citigroup
    Thu Feb 15, 11:02
    hold
    downgrade
  • Citigroup
    Wed Feb 14, 08:33
    hold
    downgrade
  • Goldman Sachs
    Thu Feb 1, 07:03
    buy
    initial